Sub menu

 
 

Australian Public Assessment Reports (AusPAR)

Search our AusPAR dataset.

An AusPAR provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve an application.

For more information see Australian Public Assessment Reports for prescription medicines (AusPARs).

Use the filters below to narrow your search.

Filter results

You can narrow down the results using the filters.

Sponsor

Topics

AusPAR Date

1062 result(s) found, displaying 201 to 225

  • AusPAR: lemborexant

    Australian Public Assessment Report (AusPAR)
    New AusPAR for Dayvigo (lemborexant) for the treatment of insomnia.

  • AusPAR: Tixagevimab and cilgavimab

    Australian Public Assessment Report (AusPAR)
    New AusPAR for EVUSHELD (tixagevimab and cilgavimab) for pre-exposure prophylaxis of COVID-19 in adults and adolescents aged 12 years older

  • AusPAR: Eptinezumab

    Australian Public Assessment Report (AusPAR)
    New AusPAR for Vyepti (eptinezumab) for the preventive treatment of migraine in adults.

  • AusPAR: Elasomeran

    Australian Public Assessment Report (AusPAR)
    Australian Public Assessment Report for Elasomeran

  • AusPAR: ChAdOx-1-S

    Australian Public Assessment Report (AusPAR)
    New AusPAR for Vaxzevria (ChAdOx-1-S) for the prevention of COVID-19 caused by SARS-CoV-2

  • AusPAR: Molnupiravir

    Australian Public Assessment Report (AusPAR)
    Australian Public Assessment Report for Molnupiravir

  • AusPAR: Tozinameran

    Australian Public Assessment Report (AusPAR)
    Australian Public Assessment Report for Tozinameran

  • AusPAR: Bevacizumab

    Australian Public Assessment Report (AusPAR)
    New AusPAR for Abevmy (bevacizumab) for the treatment of various types of cancers.

  • AusPAR: nirmatrelvir/ritonavir

    Australian Public Assessment Report (AusPAR)
    Australian Public Assessment Report for nirmatrelvir/ritonavir

  • AusPAR: Rabies immunoglobulin

    Australian Public Assessment Report (AusPAR)
    New AusPAR for KamRAB (rabies immunoglobulin) for the treatment of passive, transient post-exposure prophylaxis of rabies infection.

  • AusPAR: Tocilizumab (rch)

    Australian Public Assessment Report (AusPAR)
    New AusPAR for ACTEMRA Tocilizumab (rch) for the treatment of coronavirus disease 2019 (COVID-19).

  • AusPAR: Elasomeran (mRNA-1273)

    Australian Public Assessment Report (AusPAR)
    Australian Public Assessment Report for Elasomeran (mRNA-1273)

  • AusPAR: Pegvaliase

    Australian Public Assessment Report (AusPAR)
    Australian Public Assessment Report for Pegvaliase

  • AusPAR: Regdanvimab

    Australian Public Assessment Report (AusPAR)
    Australian Public Assessment Report for Regdanvimab

  • AusPAR: Adalimumab

    Australian Public Assessment Report (AusPAR)
    Australian Public Assessment Report for Adalimumab

  • AusPAR: Casirivimab/imdevimab

    Australian Public Assessment Report (AusPAR)
    Australian Public Assessment Report for Casirivimab/imdevimab

  • AusPAR: BNT162b2 (mRNA)

    Australian Public Assessment Report (AusPAR)
    Australian Public Assessment Report for BNT162b2 (mRNA)

  • AusPAR: ChAdOx1-S

    Australian Public Assessment Report (AusPAR)
    Australian Public Assessment Report for ChAdOx1-S - COVID-19 Vaccine AstraZeneca

  • AusPAR: Pertuzumab/trastuzumab

    Australian Public Assessment Report (AusPAR)
    Australian Public Assessment Report for Pertuzumab/trastuzumab

Help us improve the Therapeutic Goods Administration site